Spots Global Cancer Trial Database for relapsed acute myeloid leukemia
Every month we try and update this database with for relapsed acute myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | NCT06017258 | Refractory Acut... Relapsed Acute ... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CD371-YSNVZ-IL1... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS | NCT04893915 | Relapsed Acute ... Refractory Acut... Myelodysplastic... | Cytokine-induce... Fludarabine Cyclophosphamid... Donor Leukapher... Interleukin-2 | 18 Years - | Washington University School of Medicine | |
| Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | NCT04582864 | Relapsed Acute ... | Flotetuzumab Donor lymphocyt... | 18 Years - | Washington University School of Medicine | |
| Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | NCT05362942 | Relapsed Acute ... Refractory Acut... Minimal Residua... | Venetoclax, Dec... | 18 Years - | Beijing 302 Hospital | |
| Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML | NCT04354025 | Refractory Acut... Relapsed Acute ... | Cytokine induce... Fludarabine Ara-C G-CSF Interleukin-2 Leukapheresis | 1 Year - 21 Years | Washington University School of Medicine | |
| Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia | NCT02096289 | Acute Myeloid L... | Thioridazine | 55 Years - 80 Years | Ontario Clinical Oncology Group (OCOG) | |
| Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT01961765 | Relapsed Acute ... Refractory Acut... | cabozantinib | 18 Years - | Massachusetts General Hospital | |
| Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | NCT02109627 | Acute Myeloid L... Relapsed Acute ... Refractory Acut... | Ficlatuzumab Cytarabine | 18 Years - | University of California, San Francisco | |
| Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03347994 | Acute Myeloid L... | Minnelide | 18 Years - | University of Miami | |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT05703542 | Acute Myeloid L... Myelodysplastic... | BXCL701 | 18 Years - | Dana-Farber Cancer Institute | |
| FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | NCT04891757 | Advanced Hemato... Relapsed Acute ... Refractory Acut... Relapsed Myelod... Refractory Myel... Relapsed Chroni... Refractory Chro... | FHD-286 Low Dose Cytara... Decitabine | 16 Years - | Foghorn Therapeutics Inc. | |
| Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia | NCT02996474 | Relapsed Acute ... | Pembrolizumab Decitabine | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02204085 | Acute Myeloid L... Recurrent Adult... | GO-203-2c GO-203-2c + Dec... | 18 Years - | Beth Israel Deaconess Medical Center | |
| Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT06177067 | Refractory Acut... Relapsed Acute ... Acute Leukemia ... | Revumenib Venetoclax Azacitidine intrathecal (IT... Cytarabine Methotrexate | 1 Year - 30 Years | St. Jude Children's Research Hospital | |
| Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | NCT01943682 | Acute Myeloid L... Acute Lymphobla... Burkitt Lymphom... Diffuse Large C... Gray Zone Lymph... Lymphoblastic L... Anaplastic Larg... Hodgkin Lymphom... | CPX-351 | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | NCT01037556 | Acute Myelogeno... Acute Lymphocyt... | PR104 | 18 Years - | Proacta, Incorporated | |
| Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | NCT04582864 | Relapsed Acute ... | Flotetuzumab Donor lymphocyt... | 18 Years - | Washington University School of Medicine | |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | NCT04797767 | Acute Biphenoty... Acute Myeloid L... Mixed Phenotype... Myeloid Neoplas... Relapsed Acute ... Relapsed Acute ... Relapsed Mixed ... Relapsed Myeloi... Refractory Acut... Refractory Acut... Refractory Mixe... Refractory Myel... Recurrent Myelo... | Cladribine Cytarabine Mitoxantrone Recombinant Gra... Venetoclax | 18 Years - | University of Washington | |
| A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02204085 | Acute Myeloid L... Recurrent Adult... | GO-203-2c GO-203-2c + Dec... | 18 Years - | Beth Israel Deaconess Medical Center | |
| A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT05028751 | Acute Myeloid L... Relapsed Acute ... Refractory Acut... | Lanraplenib Gilteritinib | 18 Years - | Kronos Bio | |
| Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia | NCT02096289 | Acute Myeloid L... | Thioridazine | 55 Years - 80 Years | Ontario Clinical Oncology Group (OCOG) | |
| Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03347994 | Acute Myeloid L... | Minnelide | 18 Years - | University of Miami | |
| BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT05703542 | Acute Myeloid L... Myelodysplastic... | BXCL701 | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
